Results 141 to 150 of about 983,540 (218)

Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals [PDF]

, 2021
Duaa W. Al‐Sadeq, Farah M. Shurrab, Ahmed Ismail, Fathima Humaira Amanullah, Swapna Thomas, Nader Al‐Dewik, Hadi M. Yassine, Hanan F. Abdul Rahim, Laith J. Abu‐Raddad, Gheyath K. Nasrallah   +9 more
openalex   +1 more source

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Nature Medicine, 2021
H. Chemaitelly, H. Yassine, F. Benslimane, H. A. Al Khatib, P. Tang, M. Hasan, J. Malek, P. Coyle, H. Ayoub, Z. Al Kanaani, E. Al Kuwari, A. Jeremijenko, A. Kaleeckal, A. Latif, R. M. Shaik, H. A. Abdul Rahim, Gheyath K Nasrallah, M. A. Al Kuwari, H. A. Al Romaihi, M. H. Al-Thani, A. Al Khal, A. Butt, R. Bertollini, L. Abu-Raddad   +23 more
semanticscholar   +1 more source

Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial

npj Vaccines
Fractional dosing can be a cost-effective vaccination strategy to accelerate individual and herd immunity in a pandemic. We assessed the immunogenicity and safety of primary intradermal (ID) vaccination, with a 1/5th dose compared with the standard ...
M. Prins, G. Roozen, C. R. Pothast, Wesley Huisman, R. V. van Binnendijk, G. den Hartog, Vincent P Kuiper, C. Prins, J. Janse, Olivia A. C. Lamers, J. R. Koopman, A. Kruithof, I. Kamerling, R. C. Dijkland, A. D. de Kroon, Shohreh Azimi, M. Feltkamp, M. Kuijer, S. Jochems, M. Heemskerk, F. Rosendaal, M. Roestenberg, L. G. Visser, A. Roukens   +23 more
semanticscholar   +1 more source

mRNA-1273 cinical development program [PDF]

COVID-02-Miller-508 ...

core  

Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study [PDF]

, 2023
Chiara Suffritti, Roberta Gualtierotti, Sara Arcudi, Alessandro Ciavarella, Cristina Novembrino, Anna Lecchi, Silvia La Marca, Lidia Padovan, Erica Scalambrino, Marigrazia Clerici, Patrizia Bono, Ferruccio Ceriotti, Antonio Muscatello, Simona Maria Siboni, Flora Peyvandi   +14 more
openalex   +1 more source

Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial [PDF]

, 2023
Dean Follmann, Holly Janes, Eric Chun‐Pu Chu, Lakshmi Jayashankar, Christos J. Petropoulos, Leonid Serebryannyy, Robin Carroll, Naz Jean-Baptiste, Sandeep Narpala, Bob C. Lin, Adrian B. McDermott, Richard M. Novak, Daniel S. Graciaa, Stephanie Rolsma, Craig A. Magaret, Nicole A. Doria‐Rose, Lawrence Corey, Kathleen M. Neuzil, Rolando Pajón, Jacqueline M. Miller, Rubén O. Donis, Richard A. Koup, Lindsey R. Baden, Hana M. El Sahly   +23 more
openalex   +1 more source

Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era

Vaccines
Background/Objectives: COVID-19 continues to challenge public health due to emerging variants. To mitigate this, the Korea Disease Control and Prevention Agency (KDCA) recommends annual COVID-19 vaccination, but uptake remains suboptimal.
Jaehee Jung, Dain Lee, Hee-Do Yang, Ah-Young Kim, Haeun Lee, Minkyoung Kang, Ekkehard Beck, Keya Joshi, Youngju Kang, Hye-Young Kang   +9 more
doaj   +1 more source

Referee report. For: Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain [version 2; peer review: 1 approved]

, 2022
Manushak Avagyan
openalex   +1 more source

mRNA-1273 vaccination protects against SARS-CoV-2–elicited lung inflammation in nonhuman primates [PDF]

, 2022
Adam T. Waickman, Kaitlin Victor, Krista L. Newell, Tao Li, Heather Friberg, Kathryn E. Foulds, Mario Roederer, Diane L. Bolton, Jeffrey R. Currier, Robert A. Seder   +9 more
openalex   +1 more source

Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults

Human Vaccines & Immunotherapeutics
A multicomponent vaccine against seasonal influenza and COVID-19 could reduce disease burden in adults by providing simultaneous protection in a single-dose regimen.
Amanda K. Rudman Spergel, Carole Henry, Raffael Nachbagauer, Paulina Kaplonek, Eleanor Astley, Andrei Avanesov, Harry Bertera, Lizbeth Carmona, Deniz Cizmeci, Avi Collins, Alan Embry, Ruiting Guo, Xuezhou Mao, Alicia Pucci, Sarah Shao, Jessica Shih-Lu-Lee, Wen-Han Yu, Daniel Brune, Laurence Chu, Muhammad Irfan, Galit Alter, Jintanat Ananworanich, Christine A. Shaw   +22 more
doaj   +1 more source